As Perrigo Company PLC looks ahead in its transformation, it leverages its traditional strength of being first to launch generics of OTC brands for its latest portfolio expansion.
The Dublin-based firm on 1 March announced approval from the US Food and Drug Administration for OTC 125-mg
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?